Compare Cytokinetics Inc (CYTK) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Kaltura Inc — how do they compare? Cytokinetics Inc trades at $62.1 (market cap $8.62B), while Kaltura Inc trades at $1.32 (market cap $199.08M). The key difference: Cytokinetics Inc is far larger — about 43.3× Kaltura Inc's market cap, and Kaltura Inc is more actively traded (175,927 versus 2,594,626). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Kaltura Inc for 21 Days on average.
| CYTK | KLTR | |
|---|---|---|
Market Cap | $8.62B | $199.08M |
Volume | 2,594,626 | 175,927 |
Sector | Health | Technology |
52-Week High | $87.26 | $1.89 |
52-Week Low | $54.76 | $1.08 |
Typical Hold Time | 19 Days | 21 Days |
Enterprise Value | $8.72B | $211.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
KLTR trades at $1.315, down 1.13% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals, with revenue stable around $181M in 2025 and a narrowing net loss of -$12.07M, though profitability remains negative. Recent news highlights AI-driven innovations and industry recognition, including a Gartner leadership mention in August 2026. Analyst sentiment is mixed with a 44% buy rating.
The outlook hinges on KLTR's ability to monetize its AI and video platform investments to achieve sustained profitability. Key risks include high debt levels, persistent negative margins, and competitive pressures. Upside potential exists if the company converts its technological accolades into revenue growth and positive earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
